

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check

### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



| Section 1. Identifying Inform   | ation                              |                          |  |
|---|------------------------------------|--------------------------|--|
| Given Name (First Name)     Marco   | 2. Surname (Last Name)<br>Montillo |                          | 3. Date<br>29-May-2014   |
| 4. Are you the corresponding author?  | Yes No                             |                          |  |
| 5. Manuscript Title<br>Bendamustine and subcutaneous Alem<br>Relapsed/Refractory Chronic Lymphocy<br>6. Manuscript Identifying Number (if you kn<br>HAEMATOL/2014/106740          | tic Leukemia Patients              | s an effective treatmen  | nt in  |
|   |                                    |                          |  |
| Section 2. The Work Under Co  | onsideration for Pub               | lication                 |  |
| Did you or your institution <b>at any time</b> recei<br>any aspect of the submitted work (including<br>statistical analysis, etc.)?<br>Are there any relevant conflicts of intere | but not limited to grants,         | data monitoring board, s | nent, commercial, private foundation, etc.) for tudy design, manuscript preparation, |
| If yes, please fill out the appropriate info<br>Excess rows can be removed by pressing  |                                    | ave more than one ent    | tity press the "ADD" button to add a row.  |
| Name of Institution/Company   | Grant? Personal N                  | on-Financial Other?      | Comments   |
| Mundipharma   | <b>V</b>                           |                          |  |
| Genzyme   |                                    |                          |  |
|   |                                    |                          |  |
|   |                                    |                          |  |
| Section 3. Relevant financial   | activities outside the             | e submitted work.        |  |
| Place a check in the appropriate boxes i<br>of compensation) with entities as descri<br>clicking the "Add +" box. You should rep  | bed in the instructions.           | Use one line for each e  | ntity; add as many lines as you need by  |
| Are there any relevant conflicts of intere  |                                    |                          |  |
| If yes, please fill out the appropriate info  | ormation below.                    |                          |  |
| Name of Entity  | Grant? Personal N                  | on-Financial Other?      | Comments   |
| Roche   |                                    |                          |  |
| Mundipharma   |                                    | <b>v</b>                 |  |



| Name of Entity  | Grant?   | Personal Fees? | Non-Financial Support? | Other?     | Comments                           |      |
|---|--|----------------|------------------------|------------|------------------------------------|------|
| Glaxo   |  | rees           | Support <b>✓</b>       |            |                                    |      |
| Janssen   |  | <u></u>        |                        |            |                                    |      |
| Gilead  |  | ~              |                        |            |                                    |      |
|   |  |                |                        |            |                                    |      |
| Costion 4   |  |                |                        |            |                                    |      |
| Section 4. Intellectual Propert   | y Pate   | ents & Co      | pyrights               |            |                                    |      |
| Do you have any patents, whether plann  | ied, pend  | ing or issue   | ed, broadly releva     | ant to the | work? Yes V                        |      |
|   |  |                |                        |            |                                    |      |
| Section 5. Relationships not o  | overed   | above          |                        |            |                                    |      |
| Are there other relationships or activities   |  |                | perceive to have       | influence  | d, or that give the appearance of  |      |
| potentially influencing, what you wrote   |  |                |                        |            |                                    |      |
| Yes, the following relationships/cond   | Yes, the following relationships/conditions/circumstances are present (explain below): |                |                        |            |                                    |      |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest |  |                |                        |            |                                    |      |
| And the first first transfer  |  |                |                        | 1          |                                    |      |
| At the time of manuscript acceptance, jo<br>On occasion, journals may ask authors to            |  |                |                        |            |                                    | nts. |
|   |  |                |                        |            |                                    |      |
| Section 6. Disclosure Stateme   | nt   |                |                        |            |                                    |      |
| Based on the above disclosures, this form   |  | nmatically     | nenerate a disclo      | sure state | ment which will appear in the box  |      |
| below.  | ii wiii aac  | omatically     | generate a discio      | sare state | ment, which will appear in the box |      |
|   |  |                |                        |            |                                    |      |
| Dr. Montillo reports grants from Mundip   |  |                |                        |            |                                    |      |
| personal fees from Roche, personal fees support from Glaxo, personal fees from                  |  |                |                        |            |                                    |      |
|   | - / [  | - 1-           |                        |            | •                                  |      |
|   |  |                |                        |            |                                    |      |



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### 1. Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

patent

Tedeschi 1



| Section 1. Identifying Inform   | nation                             |  |
|---|------------------------------------|--|
| 1. Given Name (First Name)<br>Alessandra  | 2. Surname (Last Name)<br>Tedeschi | 3. Date<br>29-May-2014   |
| 4. Are you the corresponding author?  | Yes V No                           | Corresponding Author's Name  Marco Montillo  |
| 5. Manuscript Title Bendamustrine and subcutaneous Alem Relapsed/Refractory Chronic Lymphocy                              | rtic Leukemia Patients             | an effective treatment in  |
| 6. Manuscript Identifying Number (if you kn<br>HAEMATOL/2014/106740   | now it)                            |  |
| Section 2. The Work Under Co  | onsideration for Publi             |  |
| Did you or your institution <b>at any time</b> recei  | ive payment or services from       | a third party (government, commercial, private foundation, etc.) for   |
| any aspect of the submitted work (including<br>statistical analysis, etc.)?<br>Are there any relevant conflicts of intere |                                    | ata monitoring board, study design, manuscript preparation,  |
| The there any relevant commets of interes   |                                    |  |
| Section 3. Polyvant financial   | activities outside the             | ماريخ المستفادية   |
| Relevant financial  | activities outside the             | submitted work.  |
| of compensation) with entities as descri  | ibed in the instructions. U        | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication. |
| Are there any relevant conflicts of intere  | est? Yes No                        |  |
|   |                                    |  |
| Section 4. Intellectual Proper  | ty Patents & Copyri                | ghts   |
| Do you have any patents, whether plant  |                                    |  |

Tedeschi



| Section 5.        |  |
|-------------------|--|
| Section 5.        | Relationships not covered above  |
|                   | elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?  |
| Yes, the follo    | wing relationships/conditions/circumstances are present (explain below):   |
| ✓ No other rela   | tionships/conditions/circumstances that present a potential conflict of interest   |
|                   | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.<br>rnals may ask authors to disclose further information about reported relationships. |
| Section 6.        |  |
|                   | Disclosure Statement   |
| Based on the abo  | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box  |
| No conflict of in | terest   |

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Tedeschi 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check

### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

GAIDANO



| Section 1. Identifying Information   | ation   |                       |                                  |         |
|--|---|-----------------------|----------------------------------|---------|
| 1. Given Name (First Name)<br>GIANLUCA   | 2. Surname (Last Name)<br>GAIDANO                                     |                       | 3. Date<br>29-May-2014           |         |
| 4. Are you the corresponding author?   | Yes V No  | Corresponding Autl    | nor's Name                       |         |
| 5. Manuscript Title<br>Bendamustine and subcutaneous Alemt<br>Relapsed/Refractory Chronic Lymphocyt  | ic Leukemia Patients  | an effective treatme  | nt in                            |         |
| 6. Manuscript Identifying Number (if you kno<br>HAEMATOL/2014/106740   | ow it)  |                       |                                  |         |
| Section 2. The Work Under Co   |   |                       |                                  |         |
| The Work Under Co  | nsideration for Publ  | ication               |                                  |         |
| Did you or your institution <b>at any time</b> received any aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of interest   | but not limited to grants, o  | 1 , 3                 |                                  |         |
| Section 3. Relevant financial a  | ctivities outside the   | submitted work.       |                                  |         |
| Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should report there any relevant conflicts of interesting the series of the series | oed in the instructions. It ort relationships that we st?    Yes   No | Jse one line for each | entity; add as many lines as you | need by |
| Name of Entity   | Grant   | on-Financial Other    | Comments                         |         |
| Roche  |   |                       |                                  |         |
| Novartis   |   |                       |                                  |         |
| Onyx   |   |                       |                                  |         |
| Amgen  | V   |                       |                                  |         |
| Celgene  |   |                       |                                  |         |
| GSK  |   |                       |                                  |         |

GAIDANO



| Section 4. Intellectual Property Patents & Copyrights  |
|--|
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No  |
| Section 5. Relationships not covered above   |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  |
| Yes, the following relationships/conditions/circumstances are present (explain below):   |
| No other relationships/conditions/circumstances that present a potential conflict of interest  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.                |
| Section 6. Disclosure Statement  |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.  |
| Dr. GAIDANO reports personal fees from Roche, personal fees and non-financial support from Novartis, personal fees from Onyx, grants and personal fees from Amgen, personal fees from Celgene, personal fees from GSK, outside the submitted work; . |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

GAIDANO 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### 1. Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Coscia 1



| Section 1. Identifying Inform   | mation                           |  |
|---|----------------------------------|--|
| 1. Given Name (First Name)<br>Marta   | 2. Surname (Last Name)<br>Coscia | 3. Date<br>29-May-2014   |
| 4. Are you the corresponding author?  | Yes Vo                           | Corresponding Author's Name<br>Marco Montillo  |
| 5. Manuscript Title<br>Bendamustine and subcutaneous Aler<br>Relapsed/Refractory Chronic Lymphoc  |                                  | an effective treatment in  |
| 6. Manuscript Identifying Number (if you k<br>HAEMATOL/2014/106740  | know it)                         |  |
| C. C. C.  |                                  |  |
| Section 2. The Work Under C   | Consideration for Public         | cation   |
|   | g but not limited to grants, da  | a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation, |
|   |                                  |  |
| Section 3. Relevant financial   | l activities outside the         | submitted work.  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo |                                  |  |
| •   |                                  |  |
|   |                                  |  |
| Section 4. Intellectual Prope   | erty Patents & Copyri            | ghts   |
| Do you have any patents, whether plan   | nned, pending or issued, br      | roadly relevant to the work? Yes V No  |

Coscia 2



| Section 5.        |  |
|-------------------|--|
| Section 5.        | Relationships not covered above  |
|                   | elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?  |
| Yes, the follow   | wing relationships/conditions/circumstances are present (explain below):   |
| ✓ No other rela   | tionships/conditions/circumstances that present a potential conflict of interest   |
|                   | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.<br>rnals may ask authors to disclose further information about reported relationships. |
| Section 6.        | Disclosure Statement   |
| Based on the abo  | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box  |
| Dr. Coscia has no | othing to disclose.  |

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Coscia 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### 1. Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support. etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Belsito Petrizzi



| Section 1. Identifying Inforn  | nation                                     |   |
|--|--|---|
| 1. Given Name (First Name)<br>Valeria  | 2. Surname (Last Name)<br>Belsito Petrizzi | 3. Date<br>30-May-2014  |
| 4. Are you the corresponding author?   | Yes No                                     | Corresponding Author's Name<br>Marco Montillo   |
| 5. Manuscript Title<br>Bendamustine and subcutaneous Alem<br>Relapsed/Refractory Chronic Lymphoc | ytic Leukemia Patients                     | an effective treatment in   |
| 6. Manuscript Identifying Number (if you ki<br>HAEMATOL/2014/106740                              | now it)                                    | _   |
| Section 2. The Work Under C  | onsideration for Publ                      | ication   |
| Did you or your institution <b>at any time</b> rece  | eive payment or services fron              | n a third party (government, commercial, private foundation, etc.) for<br>ata monitoring board, study design, manuscript preparation,   |
| Are there any relevant conflicts of inter  | est? Yes No                                |   |
| Section 3. Polovant financial  |  |   |
| Relevant financial   | activities outside the                     | submitted work.   |
| of compensation) with entities as descr  | ibed in the instructions. U                | nether you have financial relationships (regardless of amount<br>Ise one line for each entity; add as many lines as you need by<br>ere <b>present during the 36 months prior to publication</b> . |
| Are there any relevant conflicts of inter  | est? Yes V No                              |   |
|  |  |   |
| Section 4. Intellectual Prope  | rty Patents & Copyri                       | ghts  |
| Do you have any patents, whether plan  | ned, pending or issued, b                  | proadly relevant to the work? Yes V No  |

Belsito Petrizzi



| Section 5.         |  |
|--------------------|--|
| Section 5.         | Relationships not covered above  |
|                    | elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?  |
| Yes, the follow    | wing relationships/conditions/circumstances are present (explain below):   |
| ✓ No other rela    | tionships/conditions/circumstances that present a potential conflict of interest   |
|                    | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.<br>rnals may ask authors to disclose further information about reported relationships. |
| Section 6.         | Disclosure Statement   |
| Based on the abo   | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box  |
| Dr. Belsito Petriz | zi has nothing to disclose.  |

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Belsito Petrizzi 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### 1. Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Orlandi



| Section 1. Identifying Inform   | mation                            |  |
|---|-----------------------------------|--|
| 1. Given Name (First Name)<br>Ester   | 2. Surname (Last Name)<br>Orlandi | 3. Date<br>29-May-2014   |
| 4. Are you the corresponding author?  | Yes Vo                            | Corresponding Author's Name<br>Marco Montillo  |
| 5. Manuscript Title<br>Bendamustine and subcutaneous Aler<br>Relapsed/Refractory Chronic Lymphoc  |                                   | an effective treatment in  |
| 6. Manuscript Identifying Number (if you k<br>HAEMATOL/2014/106740  | know it)                          |  |
| Section 2   |                                   |  |
| Section 2. The Work Under C   | Consideration for Public          | cation   |
|   | g but not limited to grants, da   | a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation, |
|   |                                   |  |
| Section 3. Relevant financia  | l activities outside the          | submitted work.  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> . |                                   |  |
| Are there any relevant conflicts of inter   | rest? Yes V No                    |  |
|   |                                   |  |
| Section 4. Intellectual Prope   | erty Patents & Copyrig            | white  |
| intellectual Prope  | erty Patents & Copyri             | giits  |
| Do you have any patents, whether plan   | nned, pending or issued, br       | roadly relevant to the work? Yes No  |
|   |                                   |  |

Orlandi 2



| Section 5.        |  |
|-------------------|--|
| Section 5.        | Relationships not covered above  |
|                   | elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?  |
| Yes, the follow   | wing relationships/conditions/circumstances are present (explain below):   |
| ✓ No other rela   | tionships/conditions/circumstances that present a potential conflict of interest   |
|                   | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.<br>rnals may ask authors to disclose further information about reported relationships. |
| Section 6.        | Disclosure Statement   |
|                   |  |
| Based on the abo  | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box  |
| Dr. Orlandi has n | nothing to disclose.   |

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Orlandi 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### 1. Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Cascavilla 1



| Section 1. Identifying Information   |                                      |   |  |
|--|--------------------------------------|---|--|
| 1. Given Name (First Name)<br>Nicola   | 2. Surname (Last Name)<br>Cascavilla | 3. Date<br>29-May-2014                      |  |
| 4. Are you the corresponding author?   | Yes V No                             | Corresponding Author's Name  Marco Montillo |  |
| 5. Manuscript Title "Bendamustine and subcutaneous Alemtuzumab combination is an effective treatment in "Bendamustine and subcutaneous Alemtuzumab combination is an effective treatment in Relapsed/Refractory Chronic 6. Manuscript Identifying Number (if you know it) HAEMATOL/2014/104356   |                                      |   |  |
| Section 2. The Work Under (  | Consideration for Public             | cation                                      |  |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No  |                                      |   |  |
| Section 3. Relevant financia   | l activities outside the             | submitted work.                             |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes V |                                      |   |  |
| Section 4. Intellectual Prope  | erty Patents & Copyrig               | ghts  |  |
| Do you have any patents, whether pla   |                                      |   |  |

Cascavilla 2



| Section 5.  |  |  |  |  |
|---|--|--|--|--|
| Section 5.  | Relationships not covered above  |  |  |  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? |  |  |  |  |
| Yes, the follo  | wing relationships/conditions/circumstances are present (explain below):   |  |  |  |
| ✓ No other rela   | No other relationships/conditions/circumstances that present a potential conflict of interest  |  |  |  |
|   | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.<br>rnals may ask authors to disclose further information about reported relationships. |  |  |  |
| Section 6.  |  |  |  |  |
| Section 6.  | Disclosure Statement   |  |  |  |
| Based on the abo  | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box  |  |  |  |
| Dr. Cascavilla ha   | s nothing to disclose.   |  |  |  |

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Cascavilla 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Ghia 1



| Section 1. Identifying Information  | ation                          |   |                           |
|---|--------------------------------|---|---------------------------|
| 1. Given Name (First Name)<br>Paolo   | 2. Surname (Last Name)<br>Ghia |   | 3. Date<br>28-May-2014    |
| 4. Are you the corresponding author?  | Yes V No                       | Corresponding Author's Na<br>Marco Montillo | ame                       |
| 5. Manuscript Title<br>The combination of Bendamustine and s<br>Refractory Patients With Chronic Lymph  |                                | nab (BenCam) is an effectiv                 | ve treatment in Relapsed/ |
| 6. Manuscript Identifying Number (if you kno<br>HAEMATOL/2014/106740  | ow it)                         | _   |                           |
| Section 2. The World Under Co   |                                |   |                           |
| The Work Under Co   | nsideration for Public         | cation                                      |                           |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No   |                                |   |                           |
| Section 3. Relevant financial a   | ctivities outside the s        | submitted work.                             |                           |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest?    Yes    No  If yes, please fill out the appropriate information below. |                                |   |                           |
| Name of Entity  | Grant                          | n-Financial other? Co                       | mments                    |
| Roche   | <b>V</b>                       |   |                           |
| Gilead  |                                |   |                           |
| Mundipharma   |                                |   |                           |
| GSK   |                                |   |                           |
| MERCK   |                                |   |                           |

Ghia



| Sortion 4  |
|--|
| Section 4. Intellectual Property Patents & Copyrights  |
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo  |
| Section 5. Relationships not covered above   |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  |
| Yes, the following relationships/conditions/circumstances are present (explain below):   |
| No other relationships/conditions/circumstances that present a potential conflict of interest  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.<br>On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement  |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.  |
| Dr. Ghia reports grants from Roche, personal fees from Gilead, personal fees from Mundipharma, grants from GSK, personal fees from MERCK, outside the submitted work; .  |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Ghia 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### 1. Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Motta 1



| Section 1. Identifying Inform   | nation                          |   |  |
|---|---------------------------------|---|--|
| 1. Given Name (First Name)<br>Marina  | 2. Surname (Last Name)<br>Motta | 3. Date<br>29-May-2014                      |  |
| 4. Are you the corresponding author?  | Yes V No                        | Corresponding Author's Name  Marco Montillo |  |
| <ol> <li>Manuscript Title</li> <li>Bendamustine and subcutaneous Alem</li> <li>Relapsed/Refractory Chronic Lymphocy</li> <li>Manuscript Identifying Number (if you known)</li> </ol>  | tic Leukemia Patients           | an effective treatment in                   |  |
| HAEMATOL/2014/106740  |                                 |   |  |
| Section 2. The Work Under Co  | onsideration for Publi          | cation                                      |  |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No   |                                 |   |  |
|   |                                 |   |  |
| Section 3. Relevant financial   | activities outside the          | submitted work.                             |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes No |                                 |   |  |
|   |                                 |   |  |
| Section 4. Intellectual Proper  | rty Patents & Copyric           | ghts  |  |
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo   |                                 |   |  |

Motta 2



| Section 5.  |  |  |  |
|---|--|--|--|
| Section 5.  | Relationships not covered above  |  |  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? |  |  |  |
| Yes, the follo  | wing relationships/conditions/circumstances are present (explain below):   |  |  |
| No other relationships/conditions/circumstances that present a potential conflict of interest   |  |  |  |
|   | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.<br>rnals may ask authors to disclose further information about reported relationships. |  |  |
| Section 6.  |  |  |  |
|   | Disclosure Statement   |  |  |
| Based on the abo<br>below.  | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box  |  |  |
| Dr. Motta has no  | othing to disclose.  |  |  |

#### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Motta 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### 1. Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Gallamini 1



| Section 1. Identifying Inform   | nation                              |   |  |
|---|-------------------------------------|---|--|
| 1. Given Name (First Name)<br>Andrea  | 2. Surname (Last Name)<br>Gallamini | 3. Date<br>29-May-2014                                |  |
| 4. Are you the corresponding author?  | Yes Vo                              | Corresponding Author's Name<br>Marco Montillo         |  |
| 5. Manuscript Title<br>"Bendamustine and subcutaneous Ale<br>Lymphocytic Leukemia Patients"   | mtuzumab combination is             | an effective treatment in Relapsed/Refractory Chronic |  |
| 6. Manuscript Identifying Number (if you k<br>HAEMATOL/2014/104356  | now it)                             |   |  |
|   |                                     |   |  |
| Section 2. The Work Under C   | Consideration for Publi             | cation  |  |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No   |                                     |   |  |
| Section 3. Relevant financial   | activities outside the              | submitted work.                                       |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes No |                                     |   |  |
| Section 4. Intellectual Prope   | erty Patents & Copyri               | abts  |  |
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No   |                                     |   |  |

Gallamini



| Section 5.  |  |  |  |
|---|--|--|--|
| Section 5.  | Relationships not covered above  |  |  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? |  |  |  |
| Yes, the follo  | wing relationships/conditions/circumstances are present (explain below):   |  |  |
| No other relationships/conditions/circumstances that present a potential conflict of interest   |  |  |  |
|   | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.<br>rnals may ask authors to disclose further information about reported relationships. |  |  |
| Section 6.  |  |  |  |
|   | Disclosure Statement   |  |  |
| Based on the abo<br>below.  | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box  |  |  |
| Dr. Gallamini ha  | s nothing to disclose.   |  |  |

#### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Gallamini 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### 1. Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

FRUSTACI 1



| Section 1. Identifying Information  |                                    |  |  |
|---|------------------------------------|--|--|
| 1. Given Name (First Name)<br>ANNA MARIA  | 2. Surname (Last Name)<br>FRUSTACI | 3. Date<br>28-May-2014                     |  |
| 4. Are you the corresponding author?  | Yes No                             | Corresponding Author's Name MARCO MONTILLO |  |
| <ol> <li>Manuscript Title</li> <li>Bendamustine and subcutaneous Alen<br/>an effective treatment in Relapsed/Ref</li> </ol>   |                                    | tic Leukemia Patients                      |  |
| 6. Manuscript Identifying Number (if you k<br>HAEMATOL/2014/106740  |                                    |  |  |
| Continue  |                                    |  |  |
| Section 2. The Work Under C   | onsideration for Public            | cation                                     |  |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No   |                                    |  |  |
| Section 3. Relevant financial   | activities outside the             | submitted work                             |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes No |                                    |  |  |
| Continue  |                                    |  |  |
| Section 4. Intellectual Prope   | rty Patents & Copyri               | ghts                                       |  |
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo   |                                    |  |  |

FRUSTACI



| Section 5.  |  |  |  |
|---|--|--|--|
| Section 5.  | Relationships not covered above  |  |  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? |  |  |  |
| Yes, the follo  | wing relationships/conditions/circumstances are present (explain below):   |  |  |
| No other relationships/conditions/circumstances that present a potential conflict of interest   |  |  |  |
|   | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.<br>rnals may ask authors to disclose further information about reported relationships. |  |  |
| Section 6.  |  |  |  |
| Section 6.  | Disclosure Statement   |  |  |
| Based on the abo  | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box  |  |  |
| Dr. FRUSTACI ha   | s nothing to disclose.   |  |  |

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

FRUSTACI 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### 1. Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

patent

Rossi 1



| Section 1. Identifying Information  |                                 |   |  |
|---|---------------------------------|---|--|
| 1. Given Name (First Name)<br>Davide  | 2. Surname (Last Name)<br>Rossi | 3. Date<br>29-May-2014                      |  |
| 4. Are you the corresponding author?  | Yes V No                        | Corresponding Author's Name  Marco Montillo |  |
| 5. Manuscript Title Bendamustine and subcutaneous Alemtuzumab combination is an effective treatment in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients  |                                 |   |  |
| 6. Manuscript Identifying Number (if you kr<br>HAEMATOL/2014/106740   | now it)                         |   |  |
| Section 2   |                                 |   |  |
| Section 2. The Work Under C   | onsideration for Public         | cation                                      |  |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?   |                                 |   |  |
| Are there any relevant conflicts of interest? Yes V No  |                                 |   |  |
| Section 3. Polovant financial   |                                 | 1. 20. 1                                    |  |
| Relevant financial  | activities outside the          | Submitted work.                             |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> . |                                 |   |  |
| Are there any relevant conflicts of interest? Yes V No  |                                 |   |  |
|   |                                 |   |  |
| Section 4. Intellectual Proper  | rty Patents & Copyri            | ghts  |  |
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo   |                                 |   |  |

Rossi



| Section 5.  |   |  |  |  |
|---|---|--|--|--|
| Section 5.  | Relationships not covered above   |  |  |  |
|   | Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? |  |  |  |
| Yes, the following relationships/conditions/circumstances are present (explain below):  |   |  |  |  |
| ✓ No other rela   | tionships/conditions/circumstances that present a potential conflict of interest  |  |  |  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. |   |  |  |  |
| Section 6.  | Disclosure Statement  |  |  |  |
| Based on the abo  | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box   |  |  |  |
| Dr. Rossi has not   | hing to disclose.   |  |  |  |

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Rossi 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

De Paoli



| Section 1. Identifying Inform   | ation                              |  |  |  |
|---|------------------------------------|--|--|--|
| Given Name (First Name)     Lorenzo   | 2. Surname (Last Name)<br>De Paoli | 3. Date<br>29-May-2014   |  |  |
| 4. Are you the corresponding author?  | Yes V No                           | Corresponding Author's Name<br>Marco Montillo  |  |  |
| 5. Manuscript Title Bendamustine and subcutaneous Alemtuzumab combination is an effective treatment in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients 6. Manuscript Identifying Number (if you know it) HAEMATOL/2014/106740   |                                    |  |  |  |
| Section 2. The Work Under Co  | onsideration for Public            | ation  |  |  |
| any aspect of the submitted work (including<br>statistical analysis, etc.)?<br>Are there any relevant conflicts of intere   | but not limited to grants, da      | a third party (government, commercial, private foundation, etc.) for<br>ta monitoring board, study design, manuscript preparation, |  |  |
| Section 3. Relevant financial   | activities outside the s           | ubmitted work.   |  |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo |                                    |  |  |  |
| Section 4. Intellectual Proper  | the Datanta & Commis               | lato   |  |  |
| intellectual Proper   | rty Patents & Copyrig              | nts ———  |  |  |
| Do you have any patents, whether plan   | ned, pending or issued, bro        | oadly relevant to the work? Yes V No   |  |  |

De Paoli 2



| Section 5.       |   |
|------------------|---|
| Section 5.       | Relationships not covered above   |
|                  | elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?  |
| Yes, the follow  | wing relationships/conditions/circumstances are present (explain below):  |
| ✓ No other rela  | tionships/conditions/circumstances that present a potential conflict of interest  |
|                  | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships. |
| Section 6.       | Disclosure Statement  |
| Based on the abo | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box   |
| Dr. De Paoli has | nothing to disclose.  |

## **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

De Paoli 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Nichelatti 1



| Section 1. Identifying Inform   | nation   |   |  |  |  |  |
|---|--|---|--|--|--|--|
| 1. Given Name (First Name)<br>Michele   | 2. Surname (Last Name)<br>Nichelatti   | 3. Date<br>29-May-2014                    |  |  |  |  |
| 4. Are you the corresponding author?  | Yes V No   | Corresponding Author's Name<br>Montillo M |  |  |  |  |
|   | 5. Manuscript Title<br>Bendamustine and subcutaneous Alemtuzumab combination is an effective treatment in<br>Relapsed/Refractory Chronic Lymphocytic Leukemia Patients |   |  |  |  |  |
| 6. Manuscript Identifying Number (if you ki<br>HAEMATOL/2014/106740   | now it)  |   |  |  |  |  |
| Section 2. The Work Under C   | onsideration for Publi   | cation                                    |  |  |  |  |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No                 |  |   |  |  |  |  |
| ŕ   |  |   |  |  |  |  |
| Section 3. Relevant financial   | activities outside the   | submitted work.                           |  |  |  |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> . |  |   |  |  |  |  |
| Are there any relevant conflicts of inter   | est? Yes 🗸 No  |   |  |  |  |  |
| Section 4. Intellectual Prope   | rty Patents & Copyri   | ghts                                      |  |  |  |  |
| Do you have any patents, whether plan   | ned, pending or issued, bu   | roadly relevant to the work? Yes V No     |  |  |  |  |

Nichelatti 2



| Section 5.   |  |  |  |  |  |
|--|--|--|--|--|--|
| Section 5.   | Relationships not covered above  |  |  |  |  |
|  | elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?  |  |  |  |  |
| Yes, the following relationships/conditions/circumstances are present (explain below): |  |  |  |  |  |
| ✓ No other rela  | tionships/conditions/circumstances that present a potential conflict of interest   |  |  |  |  |
|  | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.<br>rnals may ask authors to disclose further information about reported relationships. |  |  |  |  |
| Section 6.   | Disclosure Statement   |  |  |  |  |
| Based on the abo<br>below.   | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box  |  |  |  |  |
| Dr. Nichelatti ha  | s nothing to disclose.   |  |  |  |  |

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Nichelatti 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Morra 1



| Section 1.  | Identifying Inform                     | nation             |                 |                          |              |  |        |
|---|--|--------------------|-----------------|--------------------------|--------------|--|--------|
| 1. Given Name (Fi<br>Enrica   | rst Name)                              | 2. Surnar<br>Morra | ne (Last Name)  |                          |              | 3. Date<br>29-May-2014   |        |
| 4. Are you the cor  | responding author?                     | Yes                | <b>✓</b> No     | Correspond<br>Montillo M |              | r's Name   |        |
| 5. Manuscript Title<br>Bendamustine and subcutaneous Alemtuzumab combination is an effective t<br>Relapsed/Refractory Chronic Lymphocytic Leukemia Patients |  |                    |                 | reatment                 | in           |  |        |
| HAEMATOL/2014   | ntifying Number (if you kr<br>4/106740 | now it)            |                 | _                        |              |  |        |
| Section 2.  |  |                    |                 |                          |              |  |        |
| Section 2.  | The Work Under C                       | onsiderat          | ion for Publi   | cation                   |              |  |        |
| any aspect of the s<br>statistical analysis,  | ubmitted work (including               | but not lim        |                 |                          |              | nt, commercial, private foundation, et<br>idy design, manuscript preparation,                                  | c.) fo |
| Section 3.  |  |                    |                 |                          |              |  |        |
| Section 5.  | Relevant financial                     | activities         | outside the     | submitted                | work.        |  |        |
| of compensation   | ) with entities as descr               | ibed in the        | instructions. U | se one line fo           | or each en   | ial relationships (regardless of amo<br>tity; add as many lines as you need<br>36 months prior to publication. | d by   |
| _   | evant conflicts of intere              |                    | ′es □ No        | •                        |              |  |        |
| •   | out the appropriate info               |                    | elow.           |                          |              |  |        |
|   |  |                    |                 |                          |              |  |        |
| Name of Entity  |  | Grant?             |                 | n-Financial<br>Support   | Other?       | Comments   |        |
| lovartis  |  |                    | ~               |                          |              |  |        |
| oche  |  | ~                  |                 |                          |              |  |        |
| 1 undipharma  |  | ~                  |                 |                          |              |  | 1      |
|   |  |                    |                 |                          | _            |  | J      |
|   |  |                    |                 |                          |              |  |        |
| Section 4.  | Intellectual Prope                     | rty Pate           | nts & Convri    | ahts                     |              |  |        |
|   | intenectual i Topel                    | ty rate            | ms a copyri     | grits                    |              |  |        |
| Do you have any   | patents, whether plan                  | ned, pendi         | ng or issued, b | roadly releva            | int to the v | work? Yes V No   |        |
|   |  |                    |                 |                          |              |  |        |

Morra 2



| Cartion E                     |   |
|-------------------------------|---|
| Section 5.                    | Relationships not covered above   |
|                               | relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?  |
| Yes, the follo                | wing relationships/conditions/circumstances are present (explain below):  |
| No other rela                 | ationships/conditions/circumstances that present a potential conflict of interest   |
|                               | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.<br>Irnals may ask authors to disclose further information about reported relationships. |
| Section 6.                    | Disclosure Statement  |
| Based on the about the below. | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box   |
| Dr. Morra report              | ts personal fees from Novartis, grants from Roche, grants from Mundipharma, outside the submitted work; .   |

## **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Morra 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

patent

Massaia



| Section 1. Identifying Inform   | ation  |  |  |  |  |  |
|---|--|--|--|--|--|--|
| 1. Given Name (First Name)<br>Massimo   | 2. Surname (Last Name)<br>Massaia  | 3. Date<br>28-May-2014   |  |  |  |  |
| 4. Are you the corresponding author?  | Yes V No   | Corresponding Author's Name<br>Marco Montillo  |  |  |  |  |
|   | 5. Manuscript Title Bendamustine and subcutaneous Alemtuzumab combination is an effective treatment in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients |  |  |  |  |  |
| 6. Manuscript Identifying Number (if you known HAEMATOL/2014/106740   | ow it)   | _  |  |  |  |  |
| Section 2. The Work Under Co  | onsideration for Publi   | cation   |  |  |  |  |
|   |  | n a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation, |  |  |  |  |
| Are there any relevant conflicts of intere  | st? Yes No   |  |  |  |  |  |
| Section 3. Relevant financial a   | activities outside the   | submitted work.  |  |  |  |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> . |  |  |  |  |  |  |
| Are there any relevant conflicts of intere  | st? Yes V No   |  |  |  |  |  |
| Section 4. Intellectual Property  |  |  |  |  |  |  |
| Intellectual Propert  | ty Patents & Copyri  | ghts   |  |  |  |  |
| Do you have any patents, whether plann  | ned, pending or issued, b  | roadly relevant to the work? Yes Vo  |  |  |  |  |

Massaia 2



| Section 5.             |   |
|------------------------|---|
| Section 5.             | Relationships not covered above   |
|                        | elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?  |
| Yes, the follow        | wing relationships/conditions/circumstances are present (explain below):  |
| <b>✓</b> No other rela | tionships/conditions/circumstances that present a potential conflict of interest  |
|                        | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships. |
| Section 6.             | Disclosure Statement  |
| Based on the abo       | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box   |
| Dr. Massaia has r      | nothing to disclose.  |

## **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Massaia 3